期刊文献+

重组TFPI缺失突变体TFPI_(1-161)在毕赤酵母中的高效表达及功能鉴定 被引量:1

High Expression and Characterization of Recombinant Deletion Variant TFPI_(1-161) of Human Tissue Factor Pathway Inhibitor in Pichia pastoris
下载PDF
导出
摘要 人组织因子途径抑制物 (TFPI)是一种体内天然存在的外源性凝血途径特异性抑制物。缺失突变体TFPI1 - 1 6 1 仅包括TFPI的N末端、K1和K2结构域 ,是一种研究TFPI结构与功能及其相互关系的理想对照分子。以克隆质粒pGEM 3Zf( ) TFPI为模板 ,用PCR方法获得TFPI1 - 1 6 1 基因 ,构建表达质粒pPIC9K TFPI1 - 1 6 1 并转化毕赤酵母GS115。通过筛选多拷贝转化子及优化发酵培养条件 ,首次在毕赤酵母中高效表达了TFPI1 - 1 6 1 ,经纯化后最终产量高于酿酒酵母 2 0倍以上。由于糖基化程度不同 ,TFPI1 - 1 6 1 表达为TFPI1 - 1 6 1 (2 4kD)和TFPI1 - 1 6 1 (2 7kD)两种分子形式 ,其等电点分别为 4 8和 4 9。根据等电点差异 ,二者可通过阴离子交换层析得到分离 ,其活性无显著性差异。经分子筛和阴离子交换层析分离纯化后 ,从 4L发酵培养液中可分别获得 1 4gTFPI1 - 1 6 1 (2 4kD)和 1 8gTFPI1 - 1 6 1 (2 7kD) ,其比活性分别达 12 880u mg和 12 4 0 0u mg ,回收率达 5 5 %。经稀释的凝血酶原时间及发色底物法检测 ,重组TFPI1 - 1 6 1 具有良好的抗凝及抑制FXa活性的作用。为获得大量TFPI1 - 1 6 1 提供了一种廉价高效的蛋白表达纯化方式 。 Human tissue factor pathway inhibitor (TFPI) is a native specific inhibitor of extrinsic pathway of coagulation in vivo. As a kind of deletion variant which only contains N-terminus, K1 and K2 of TFPI, TFPI 1-161 is an ideal control molecule in the research of structure and function of TFPI. In this article, we not only investigated the methods of expression and purification, but also detected characteristics of TFPI 1-161. Using plasmid pGEM-3Zf(-)-TFPI as a template, DNA of TFPI 1-161 was obtained by PCR and cloned into plasmid pPIC9K to construct expression plasmid pPIC9K-TFPI 1-161. By force of screening multi-copy transformant and optimizing ferment condition, TFPI 1-161 was highly expressed in Pichia pastoris GS115 for the first time and the final yield after purification was increased more than 20-fold comparing with Saccharomyces cerevisiae. TFPI 1-161 was expressed as two different molecular weight proteins namely TFPI 1-161(24kD) and TFPI 1-161(27kD) because of difference of glycosylation. Their isoelectric points were 4.8 and 4.9 respectively. They were separated according to different isoelectric points using anion-exchange chromatography and had similar activity. Approximately 1.4g TFPI 1-161(24kD) and 1.8g TFPI 1-161(27kD) was obtained from 4-liter fermentation culture after purification by ultrafiltration, gel filtration, anion-exchange chromatography. Their specific activity were up to 12 880u/mg and 12 400u/mg respectively. The rate of recovery of TFPI 1-161 was about 55%. The recombinant TFPI 1-161 had good anticoagulant activity in diluted prothrombin time assay (dPT) and anti-FXa activity in a direct amidolytic assay. The expression and purification system described here provides a cost-effective method for generating large amounts of material for further fundamental and preclinical research of TFPI 1-161.
出处 《生物工程学报》 CAS CSCD 北大核心 2004年第6期937-942,共6页 Chinese Journal of Biotechnology
基金 国家自然科学基金 (No.3 0 2 712 2 9) 上海市重点科技攻关课题基金 (No .0 3 43 192 0 5 )资助~~
关键词 组织因子途径抑制物 TFPI1-161 表达 纯化 PICHIA PASTORIS tissue factor pathway inhibitor, TFPI 1-161, expression, purification, Pichia pastoris
  • 相关文献

参考文献19

  • 1Wesselschmidt R, Likert K, Girard T et al. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood, 1992, 79(8): 2004 - 2010 被引量:1
  • 2Nordfang O, Bjorn SE, Valentin S et al. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity.Biochemistry, 1991, 30(43): 10371 - 10376 被引量:1
  • 3Mine S, Yamazaki T, Miyata T et al. Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor. Biochemistry, 2002, 41( 1): 78- 85 被引量:1
  • 4Neels JG, van Den Berg BM, Lookene A et al. The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties.J Biol Chem, 1999, 274(44): 31305 - 31311 被引量:1
  • 5Park CT, Creasey AA, Wright SD. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Blood, 1997, 89(12): 4268-4274 被引量:1
  • 6Horie S, Hiraishi S, Hamuro T et al. Oxidized low-density lipoprotein associates strongly with carboxy-terminal domain of tissue factor pathway inhibitor and reduces the catalytic activity of the protein. Thromb Haemost, 2002, 87(1): 80 - 85 被引量:1
  • 7Johnson K, Zaror I, Bauer D et al. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor. Thromb Haemost, 1998, 80(4): 585 - 587 被引量:1
  • 8Yang Yinke, He Xiaofan, Li Juncheng et al. Preparation and characterization of monoclonal antibody against recombinant human tissue factor pathway inhibitor. Chin Med J ( Engl ), 1998, 111(8): 718- 721 被引量:1
  • 9Holst J, Lindblad B, Westerlund G et al. Pharmacokinetics and delayed experimental anti-thrombotic effect of two domain nonglycosylated tissue factor pathway inhibitor. Thromb Res, 1996, 81(4) : 461 - 470 被引量:1
  • 10Rao LV, Nordfang O, Hoang AD et al. Mechanism of antithrombinⅢ inhibition of factor Ⅶa/tissue factor activity on cell surfaces.Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor Ⅶa/tissue factor activity. Blood, 1995, 85(1): 121- 129 被引量:1

同被引文献13

  • 1任军,黄阳滨,汤其群,吴晓俐,涂宣林,顾银良,朱运松,宋后燕.基因工程链激酶的中试研究[J].药物生物技术,1996,3(2):65-68. 被引量:3
  • 2Girard TJ,Warren LA,Novotny WF,et al.Brown SG,Miletich JP.Functional significance of the Kunitz-type inhibitory domains of lipoprotein associated coagulation inhibitor[J].Nature,1989,338 (6215):518-520. 被引量:1
  • 3Bajaj Ms,Birktoft JJ,Steer SA,et al.Structure and biology of tissue factor pathway inhibitor[J].Thromb Haemost,2001,86(4):959 -972. 被引量:1
  • 4Hao Bai,Duan Ma,Yu-Gao Zhang,et al.Molecular design and characterization of recombinant long half-life mutants of human tissue factor pathway inhibitor[J].Thromb Haemost,2005,93:1055-1060. 被引量:1
  • 5Nakamura Y,Nakamura K,Ohta K,et al.anti-inflammtory effects of long-lasting locally-delivered human recombinant tissue factor pathway inhibitor after balloon angioplasty[J].Basic Res Cardiol,2002,97(3):198 -205. 被引量:1
  • 6Hembrough TA,Swartz Gm,Papath anassiu A,et al.Tissue factor/factor VⅦa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism[J].Cancer Res,2003,63 (11):2997-3000. 被引量:1
  • 7Hembrough TA,Ruiz JF,Swerdlow BM,et al.Identification and characterization of a very low density lipoprotein receptor binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity[J].Blood,2004,103 (9):3374-3380. 被引量:1
  • 8Hembrough TA,Ruiz JF,Papathanassia AE,et al.Tissue factor pathy inhibitor inhibits endothelial cell proliferation via association wth the very low density lipoprotein receptor[J].J Biol Chem,2001,276 (15):12241-12248. 被引量:1
  • 9Hamuro T,Kamikubo Y,Nakahara Y,et al.Human recombinant tissue factor pathway inhibitor induces apoptosis in cultured human endothelial cells[J].FEBS Lett,1998,421(3):197 -202. 被引量:1
  • 10Matyal R,Vin Y,Delude RL,et al.Extremely low doses of tissue factor pathway inhibitor decrease mortality in a rabbit model of septic shock[J].Intensive Care Med,2001,27(8):1274-1280. 被引量:1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部